PHAT - Phathom Pharma wins FDA approval for antibacterial tablets

New Jersey-based pharmaceutical company, Phathom Pharmaceuticals (NASDAQ:PHAT), announced that the U.S. Food and Drug Administration (FDA) approved its antibacterial drugs, Voquezna Triple Pak and Voquezna Dual Pak, for the treatment of Helicobacter pylori infection in adults. Voquezna combines antibiotics with vonoprazan, a potassium-competitive acid blocker. The oral treatments are expected to reach the U.S. market in Q3 2022, marketed exclusively by Phathom (PHAT). The approvals for the New Drug Applications were based on the Phase 3 PHALCON-HP trial, in which Voquezna Triple Pak and Voquezna Dual Pak were found to have an H. pylori eradication rate of ~85% and ~79%, respectively, compared to lansoprazole triple therapy. Phathom (PHAT) shares have surged on positive vonoprazan developments in the past Seeking Alpha Catalyst Watch highlighted last week.

For further details see:

Phathom Pharma wins FDA approval for antibacterial tablets